273 related articles for article (PubMed ID: 16782768)
1. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
2. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
[TBL] [Abstract][Full Text] [Related]
3. 1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans.
Eiermann B; Edlund PO; Tjernberg A; Dalén P; Dahl ML; Bertilsson L
Drug Metab Dispos; 1998 Nov; 26(11):1096-101. PubMed ID: 9806952
[TBL] [Abstract][Full Text] [Related]
4. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.
Dalén P; Dahl ML; Eichelbaum M; Bertilsson L; Wilkinson GR
Pharmacogenetics; 1999 Dec; 9(6):697-706. PubMed ID: 10634132
[TBL] [Abstract][Full Text] [Related]
5. Enantioselectivity of debrisoquine 4-hydroxylation in Brazilian Caucasian hypertensive patients phenotyped as extensive metabolizers.
Cerqueira PM; Mateus FH; Cesarino EJ; Bonato PS; Lanchote VL
J Chromatogr B Biomed Sci Appl; 2000 Dec; 749(2):153-61. PubMed ID: 11145052
[TBL] [Abstract][Full Text] [Related]
6. A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography.
Pereira VA; Auler JO; Carmona MJ; Mateus FH; Lanchote VL; Breimer DD; Santos SR
Braz J Med Biol Res; 2000 May; 33(5):509-14. PubMed ID: 10775881
[TBL] [Abstract][Full Text] [Related]
7. Determination of debrisoquine and metabolites in human urine by gas chromatography-mass spectrometry.
Daumas L; Sabot JF; Vermeulen E; Clapot P; Allegre F; Pinatel H; Boucherat M; Francois B
J Chromatogr; 1991 Sep; 570(1):89-97. PubMed ID: 1797839
[TBL] [Abstract][Full Text] [Related]
8. Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes.
Cooke BR; Bligh SW; Cybulski ZR; Ioannides C; Hall M
Drug Metab Dispos; 2012 Jan; 40(1):70-5. PubMed ID: 21976620
[TBL] [Abstract][Full Text] [Related]
9. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M
Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874
[TBL] [Abstract][Full Text] [Related]
10. The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.
Wink J; Veering BT; Kruit M; Burm AG; Huledal GA; Ekström GY; Stienstra R; van Kleef JW
Anesth Analg; 2008 Jan; 106(1):143-6, table of contents. PubMed ID: 18165569
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
Dalén P; Dahl M; Andersson K; Bertilsson L
Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
[TBL] [Abstract][Full Text] [Related]
12. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
Meier PJ; Mueller HK; Dick B; Meyer UA
Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
[TBL] [Abstract][Full Text] [Related]
13. Effects of terfenadine and diphenhydramine on the CYP2D6 activity in healthy volunteers.
Kortunay S; Bozkurt A; Basci NE; Kayaalp SO
Eur J Drug Metab Pharmacokinet; 2002; 27(3):171-4. PubMed ID: 12365197
[TBL] [Abstract][Full Text] [Related]
14. Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling.
Lightfoot T; Ellis SW; Mahling J; Ackland MJ; Blaney FE; Bijloo GJ; De Groot MJ; Vermeulen NP; Blackburn GM; Lennard MS; Tucker GT
Xenobiotica; 2000 Mar; 30(3):219-33. PubMed ID: 10752638
[TBL] [Abstract][Full Text] [Related]
15. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.
Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L
Br J Clin Pharmacol; 2003 Jun; 55(6):630-4. PubMed ID: 12814461
[TBL] [Abstract][Full Text] [Related]
16. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
17. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
Kallio J; Lindberg R; Huupponen R; Iisalo E
Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
[TBL] [Abstract][Full Text] [Related]
18. Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.
Simooya OO; Sijumbil G; Lennard MS; Tucker GT
Br J Clin Pharmacol; 1998 Mar; 45(3):315-7. PubMed ID: 10896408
[TBL] [Abstract][Full Text] [Related]
19. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
LLerena A; Berecz R; de la Rubia A; Fernández-Salguero P; Dorado P
Ther Drug Monit; 2001 Dec; 23(6):616-20. PubMed ID: 11802093
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A; Dorado P; Peñas-Lledó EM
Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
